Dipeptidyl peptidase-4 (DPP-4) is an enzyme that cleaves and inactivates incretin hormones 20 capable of stimulating insulin secretion from pancreatic β cells. DPP-4 inhibitors are now 21 widely used for the treatment of type 2 diabetes. Experimental studies have suggested a 22 renoprotective role of DPP-4 inhibitors in various models of diabetic kidney disease (DKD), 23 which may be independent of lowering blood glucose levels. In the present study, we examined 24 the effect of DPP-4 inhibitors in the rat Thy-1 glomerulonephritis model, a non-diabetic 25 glomerular injury model. Rats were injected with OX-7 (1.2 mg/kg, iv) and treated with the 26 DPP-4 inhibitor alogliptin (20 mg/kg/day) or vehicle for 7 days, orally by gavage. Alogliptin 27 significantly reduced the number of CD68-positive inflammatory macrophages in the kidney, 28 which was associated with a non-significant tendency to ameliorate glomerular injury and 29 reduce proteinuria. Another DPP-4 inhibitor, anagliptin, (300 mg/kg/day, mixed with food) and 30 a glucagon-like peptide-1 (GLP-1) receptor agonist, exendin-4 (10 mg/kg, sc) similarly reduced 31 CD68-positive macrophage infiltration to the kidney. Furthermore, ex vivo transmigration 32 assays using peritoneal macrophages revealed that exendin-4, but not alogliptin, 33 dose-dependently reduced monocyte chemotactic protein-1-stimulated macrophage infiltration. 34 These data suggest that DPP-4 inhibitors reduced macrophage infiltration directly via 35 GLP-1-dependent signaling in the rat Thy-1 nephritis model, and they indicate that the control 36 3 of inflammation by DPP-4 inhibitors are useful for the treatment of non-DKD models.
Introduction 41
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal L cells in 42 response to food intake. In pancreatic β cells, GLP-1 binds to its G protein-coupled receptor 43 (GLP-1R) and stimulates the adenylyl cyclase pathway, resulting in protein kinase A-mediated 44 and Epac2-mediated insulin secretions in a glucose-dependent manner. Under normal conditions, 45 GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4). Currently, DPP-4 46 resistant GLP-1R agonists and DPP-4 inhibitors are widely used as novel glucose-lowering 47
Statistical analysis 160
Data are expressed as mean ± SE, unless otherwise indicated. Statistical 
Effect of DPP-4 inhibitors on glomerular injury and proteinuria in the rat Thy-1 nephritis 167
model 168 DPP-4 inhibitors are anti-diabetic drugs acting on incretins, which exert glucose-lowering 169 effects only in hyperglycemia. Therefore, they are not likely to induce hypoglycemia in young, 170 non-diabetic animals. In a pilot study, we confirmed that alogliptin did not affect the fasting 171 blood glucose level (control: 79.8 ± 4.1 mg/dl, control alogliptin: 73.4 ± 3.3 mg/dl, Thy-1: 74.2 172 ± 2.9 mg/dl, Thy-1 alogliptin: 74.5 ± 1.9 mg/dl) or systolic blood pressure (control: 120.7 ± 6.7 173 mmHg, control alogliptin: 122.7 ± 10.5 mmHg, Thy-1: 116.4 ± 2.4 mmHg, Thy-1 alogliptin: 174
± 1.3 mmHg). 175
The rat Thy-1 nephritis model is characterized by early mesangiolysis (by day 2-3), 176 followed by subsequent mesangial cell proliferation, matrix expansion, and crescent formation12 that peaks on day 7. To see the potential effects of alogliptin at early phase in this model, we 178 performed pathological analysis, but reduction of mesangiolysis was not observed by alogliptin 179 treatment at day3 (data not shown). Thus, we next evaluated glomerular pathology on day 7. 180 Alogliptin treatment non-significantly reduced the total injury score of glomeruli (Thy-1: 35.1 ± 181
1.3, Thy-1 alogliptin: 31.4 ± 1.7; P = 0.37) ( Figure 1A -G). The number of glomeruli 182 categorized as score 0 (no injury) was slightly increased from 1.9 ± 1.1 to 7.6 ± 2.9 and that 183 belonging to score 2 (severe injury) was moderately decreased from 19.1 ± 3.7 to 12.4 ± 3.5, 184
albeit the results were not significant ( Figure 1H ). Consistent with pathological analyses, a 185 non-significant trend toward a reduction in proteinuria was observed ( Figure 1K ). Serum 186 creatinine levels were not altered in this model (control: 0.33 ± 0.03 mg/dl, control alogliptin: 187 0.30 ± 0.01 mg/dl, Thy-1: 0.36 ± 0.02 mg/dl, and Thy-1 alogliptin: 0.34 ± 0.07 mg/dl). 188
189
Equivocal impact of the DPP-4 inhibitor on oxidative stress 190 Previous studies reported that DPP-4 inhibitors exhibit renoprotective effects through 191 anti-oxidative stress in experimental DKD models (8, 22, 25) . Thus, we examined the effect of 192 alogliptin on oxidative stress by immunohistological analyses. The expression levels of the 193 anti-oxidant enzyme SOD1 in the renal cortex were decreased by disease-induction but were not 194 affected by alogliptin (Figure 2A-E) . In addition, an oxidative stress marker, nitrotyrosine was In an effort to elucidate the mechanisms underlying these observations, we examined DPP-4 224 activity in plasma and kidney homogenates and found that it was significantly reduced after the 225 induction of Thy-1 nephritis. Alogliptin further significantly reduced both plasma and renal 226 DPP-4 activity, as expected ( Figure 4A and B) . Consistently, plasma GLP-1 levels were 227 significantly increased again by treatment with alogliptin ( Figure 4C) . inhibitor ameliorated 17, 18, 22, 25) . In type 2 diabetes models, 260 GLP-1R agonists also ameliorated kidney injury (5, 27). In contrast, only a few studies have 261 examined the effects of GLP-1R agonists and DPP-4 inhibitors in non-DKD models. In AKI 262 models, the GLP-1R agonist and DPP-4 inhibitor ameliorated cisplatin-induced nephrotoxicity 263 and ischemia-reperfusion injury (6, 16). In a chronic kidney disease model, the DPP-4 inhibitor 264 attenuated renal dysfunction and structural damage in the remnant kidney (14) . 265 Shinosaki et al. previously reported that a monoclonal antibody against DPP-4 266 considerably reduced proteinuria and mesangial expansion via the suppression of the 267 complement cascade in the rat Thy-1 model (30). Contrary to this report, we observed a 268 non-significant trend toward reductions in glomerular injury and proteinuria in the present study. 269 DPP-4 (CD26), on the one hand, is an important molecule that functions as a cleaving enzyme 270 and also serves as a surface receptor and/or co-stimulatory protein, especially in immune 271 response. For example, DPP-4/CD26 is a T cell activation antigen, but its enzymatic activity is 272 not required for the signaling function in T cells (7). In addition, the expression of DPP-4/CD26, 273
but not DPP-4 activity, is associated with the susceptibility of the human immunodeficiency 274 18 virus type-1 to CD4 T lymphocytes (26). In the rat Thy-1 model, Th1 cytokines produced by 275 CD4 T lymphocytes contribute to the development of injury (12), and the suppression of 276 cytokine production could be a valid target for therapy (11). Taken together, the results of the 277 present study indicated that the expression of DPP-4, but not enzymatic activity, might be 278 important for immune responses in CD4 T lymphocytes. Thus, the inhibition of DPP-4 activity 279 only resulted in a non-significant reduction of glomerular injury and proteinuria in this model. 280 We focused on the anti-inflammatory effects of DPP-4 inhibitors. Two types of DPP-4 281 inhibitors, alogliptin and anagliptin, reduced macrophage infiltration to the injured kidney. This reduces macrophage infiltration and leads to attenuation of renal histology and proteinuria (28). 296
In our study, treatment with alogliptin resulted in a non-significant trend toward reductions in 297 glomerular injury and proteinuria. These trends were also associated with reduced macrophage 298 infiltration, and thus, these results were consistent with those of Rampino et al. However, 299 detailed molecular mechanisms involving DPP4 inhibitor suppression of macrophage 300 infiltration merit further investigation. with a reduction in the number of CD163-positive macrophages (1). These reports suggest that 312 M2-like macrophages contribute to the progression of glomerular injury in the Thy-1 nephritis 313 model. In our study, DPP-4 inhibitors, but not the GLP-1R agonist, exhibited the tendency of 314 reducing proteinuria, whereas the number of CD163-positive macrophages was not affected by 315 the treatment with the DPP-4 inhibitor, but it increased by the treatment with the GLP-1R 316 agonist. We speculate that the polarity in changes of macrophages require potent signaling of 317
GLP-1R, and that the increased number of M2-like macrophages by effects of the GLP-1R 318
agonist might have negated the renoprotective effects observed with the DPP-4 inhibitor. 319 Contrary to many published papers, reducing renal macrophage infiltration did not 320 result in significant reduction in glomerular injury and proteinuria in our study. Alogliptin was 321 administered to rats in reference with a previous paper in which pharmacokinetics of alogliptin 322 was closely examined and plasma DPP-4 inhibition in rats was observed through 12 h but not 323 24 h after single dose of 10 mg/kg alogliptin (19). To achieve constant inhibition of plasma 324 DPP-4, we administered 10 mg/kg alogliptin twice a day and significant plasma DPP-4 325 inhibition and GLP-1 increase were confirmed but failed to reduce proteinuria significantly. As 326 to exendin-4, we used the same dose as described in a previous study from another group (10 327 μg/kg/day), in which exendin-4 significantly reduced albuminuria in STZ-induced type1 328 21 diabetes model (17). In an additional experiment, rats in the Thy-1 group were treated with 329 exendin-4 (5 μg/kg twice a day) from day -7 to day 7 days, but proteinuria was not improved 330 (data not shown). Based on these, we believe that the absent reduction in proteinuria was not 331 due to insufficient DPP4 inhibition and GLP-1R stimulation, but rather because of the robust 332 degree of renal injury in which reduction in macrophage infiltration alone was not sufficient to 333 influence the disease course. 334
Takase et al. used eicosapentaenoic acid (EPA) in the same model (35). Treatment of 335
EPA significantly reduced CD68 positive macrophage infiltration into tubulointerstitial area, 336 which was associated with the prevention of tubulointerstitial injury. However, EPA did not 337 reduce CD68 positive macrophage infiltration into glomeruli and failed to reduce proteinuria, 338
suggesting that inhibition of macrophage infiltration in glomerulus is important for reducing 339 proteinuria and glomerular injury in rat Thy-1 model. Indeed, many studies showed the 340 reduction of proteinuria and glomerular injury was related to the reduction of macrophages in 341 glomeruli (3, 28). In our study, the number of CD68 positive macrophages in glomeruli was not 342 decreased by the treatment of alogliptin (data not shown). Thus, this may be another reason why 343 the reduction of macrophage infiltration did not result in reduction in glomerular injury and 344
proteinuria. 345
Apart from GLP-1, DPP-4 can cleave multiple substrates such as the brain-derived Representative periodic acid-Schiff (PAS) staining at low magnification of control, control 513 alogliptin, Thy-1, and Thy-1 alogliptin (A, B, C and D) and at high magnification of Thy-1 and 514
Thy-1 alogliptin (E and F) are shown. Bars = 500 μm (low magnification, ×40) and 100 μm 515 (high magnification, ×400). The right panels show the total glomerular injury scores (I) and the 516 distribution of scores (J). The bar graph shows urinary protein excretion levels in the control and 517
Thy-1 groups with and without alogliptin (k). Data are expressed as means ± SE. *P < 0.05 518 compared with the control group. Expressions of GLP-1R and DPP-4 were examined in RAW264, peritoneal macrophages, and 556 the kidney (used as the positive control) by PCR and agarose gel electrophoresis (A and H). 557
Boyden chamber assays using peritoneal macrophages were performed and representative 558 images are shown (exendin-4: B-F and alogliptin: I-M). Bars = 100 μm (×200). The number of 559 migrating cells were counted and expressed as a count per field (G and N). Graphs are 560 representative of three independent experiments. Data are expressed as means ± SD. *P < 0.05 561 compared with the non-treated group. † P < 0.05 MCP-1-treated group. 562 Table 1 
